Oruka Therapeutics (ORKA) SVP Arjun Agarwal Sells $28K of Stock

Arjun Agarwal, the Senior Vice President of Finance at Oruka Therapeutics, Inc. (ORKA), sold 395 shares of the company on June 15, 2026. The transaction was conducted at an average price of $69.69, totaling $27,527.55. This sale was filed with the SEC and was executed under a Rule 10b5-1 trading plan, which is a pre-set schedule that insiders use to trade shares at specific times or prices.

Agarwal's Recent Trading Activity

This small sale follows a much larger acquisition by the same executive just days earlier. On June 12, 2026, Agarwal bought 9,459 shares at a price of $15.87. Even after the June 15 sale of 395 shares, his net position in the company remains significantly higher than it was at the start of that week. The June 15 sale coincided with several other executives trimming their holdings at the same $69.69 price point, suggesting a coordinated period of liquidity for the management team.

Oruka Therapeutics Stock Performance

Shares of Oruka Therapeutics were trading at $68.86 on Monday. The stock has moved through a wide range over the last year, hitting a low of $14.89 and a high of $115.52. While the current price is down from its 50-day moving average of $96.42, it remains above the 200-day moving average of $61.44. The biotech firm currently has a market value of about $6.18 billion.

Recent Earnings and Financial Position

The company is still in its clinical stages and is not yet profitable, reporting a loss of $2.04 per share. Because of this, it does not have a traditional price-to-earnings ratio. However, Oruka maintains a healthy balance sheet for a biotech firm, with a current ratio of 38.513. This suggests the company has a large cushion of cash and short-term assets to fund its research. The next financial update is scheduled for November 11, 2026.

Insider Buying and Selling at Oruka Therapeutics, Inc.

The sale by Agarwal was part of a broader day of selling at Oruka Therapeutics on June 15, 2026. CEO Lawrence Otto Klein sold 1,729 shares, and General Counsel Paul Quinlan sold 733 shares, both at the $69.69 price. Additionally, Chief Operating Officer Laura Lee Sandler sold 600 shares that same day. Later in the year, on October 15, 2026, Chief Medical Officer Joana Goncalves sold 7,000 shares at a higher price of $74.81 through a planned trade.

Analysts Set New Price Targets

Wall Street analysts remain largely positive on the company's prospects. On September 24, 2026, Wedbush reiterated its outperform rating with a $165.00 price target. HC Wainwright & Co. also maintained a buy rating that same day with a $120.00 target. Other firms like Guggenheim and BTIG have set even higher targets, reaching up to $200.00. Across 12 different analyst opinions, the consensus is a strong buy with an average price target of $155.00.

About Oruka Therapeutics

Oruka Therapeutics is a biotechnology company based in Menlo Park, California. It focuses on developing new antibody treatments for chronic skin and joint conditions, specifically psoriasis and psoriatic arthritis. The company’s lead projects, ORKA-001 and ORKA-002, are currently moving through phase 2 clinical trials. These treatments aim to provide better long-term relief for patients by targeting specific proteins in the immune system.

What's Ahead for Oruka Therapeutics, Inc.

Investors will likely watch for clinical trial updates and the upcoming November 11 earnings report to see how the company is managing its cash burn. While insider sales can sometimes draw attention, these transactions were relatively small and, in Agarwal's case, followed a much larger buy. It is also important to remember that 13F filings and insider reports are backward-looking and may not reflect an individual's current view of the stock.